期刊文献+

深部热疗对胰腺癌免疫功能影响的研究进展 被引量:4

Research progress of deep regional hyperthermia on immunity of pancreatic cancer
下载PDF
导出
摘要 胰腺癌是全球最致命的癌症类型之一,由于胰腺特殊的解剖位置及生物学特性,其早期诊断困难,病死率高。晚期胰腺癌多采取综合治疗,深部热疗是其治疗手段之一,目前已联合手术、放疗、化疗、免疫治疗等手段运用于临床实体肿瘤治疗过程中。深部热疗对胰腺癌肿瘤细胞具有直接的杀伤作用,同时对机体免疫系统的影响也较为复杂、广泛,主要表现在对肿瘤微环境、免疫细胞及热休克蛋白等有一定的作用。本文就深部热疗对胰腺癌免疫功能方面的影响进行综述。 Pancreatic cancer is one of the most lethal cancers in the world.Because of its special anatomical location and biological characteristics,pancreatic cancer is difficult to be diagnosed early and has high mortality.Comprehensive treatment is mostly used in advanced pancreatic cancer.Deep regional hyperthermia has been used in the treatment of various solid tumors combined with surgery,radiotherapy,chemotherapy,immunological therapy and others.Hyperthermia can directly kill pancreatic cancer cells.At the same time,it has complicated and extensive influence on the immune system,which is mainly manifested in tumor microenvironment,immune cells,heat shock proteins,et al.This article reviewed the progress of deep regional hyperthermia on immunity of pancreatic cancer.
作者 李雅哲 张阳 孙婧华 LI Yazhe;ZHANG Yang;SUN Jinghua(Department of Medical Oncology,the Second Affiliated Hospital of Dalian Medical University,Dalian 116027,China)
出处 《大连医科大学学报》 CAS 2019年第2期175-178,188,共5页 Journal of Dalian Medical University
关键词 胰腺癌 热疗 免疫 pancreatic cancer hyperthermia immunity
  • 相关文献

参考文献1

二级参考文献176

  • 1Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreaticcancer: a report of treatment and survival trends for 100,313patients diagnosed from 1985-1995, using the National CancerDatabase. J Am Coll Surg 1999; 189: 1-7 [PMID: 10401733].
  • 2Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, KrisMG, Markman M, Mayer RJ, Raghavan D, Ramsey S, ReamanGH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT,Davidson NE, Schilsky RL, Lichter AS. Clinical cancer advances2007: major research advances in cancer treatment, prevention,and screening--a report from the American Society of ClinicalOncology. J Clin Oncol 2008; 26: 313-325 [PMID: 18086794DOI: 10.1200/JCO.2007.15.4088].
  • 3Cancer Facts & Figures 2015. Atlanta: American Cancer Society,2015: 1-56.
  • 4Stathis A, Moore MJ. Advanced pancreatic carcinoma: currenttreatment and future challenges. Nat Rev Clin Oncol 2010; 7:163-172 [PMID: 20101258 DOI: 10.1038/nrclinonc.2009.236].
  • 5Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW,Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, Levy MJ, ChakA, Fockens P, Goggins M, Bruno M. International Cancer ofthe Pancreas Screening (CAPS) Consortium summit on themanagement of patients with increased risk for familial pancreaticcancer. Gut 2013; 62: 339-347 [PMID: 23135763 DOI: 10.1136/gutjnl-2012-303108].
  • 6Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. ArchPathol Lab Med 2009; 133: 365-374 [PMID: 19260742 DOI: 10.1043/1543-2165-133.3.365].
  • 7Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DepinhoRA. Genetics and biology of pancreatic ductal adenocarcinoma.Genes Dev 2006; 20: 1218-1249 [PMID: 16702400 DOI: 10.1101/gad.1415606].
  • 8Ottenhof NA, Milne AN, Morsink FH, Drillenburg P, Ten Kate FJ,Maitra A, Offerhaus GJ. Pancreatic intraepithelial neoplasia andpancreatic tumorigenesis: of mice and men. Arch Pathol Lab Med2009; 133: 375-381 [PMID: 19260743 DOI: 10.1043/1543-2165-133.3.375].
  • 9Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras genemutations in the intraductal precursors of human pancreatic adenocarcinoma.Cancer Res 1997; 57: 2140-2143 [PMID: 9187111].
  • 10Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, HrubanRH, Maitra A, Kinzler K, Vogelstein B, Goggins M. Presence ofsomatic mutations in most early-stage pancreatic intraepithelialneoplasia. Gastroenterology 2012; 142: 730-733.e9 [PMID:22226782 DOI: 10.1053/j.gastro.2011.12.042].

共引文献5

同被引文献42

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部